The CCDC167 Knockout AGS Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the AGS human gastric adenocarcinoma cell line, engineered for targeted disruption of the CCDC167 gene. As a polyclonal pool, this population maintains genetic heterogeneity across the genome while carrying CRISPR-induced loss-of-function mutations at the target locus, enabling robust functional studies without the clonal selection artifacts that can confound single-cell?Cderived knockout lines.
The AGS parental cell line was established from a primary gastric adenocarcinoma of a 54-year-old female and exhibits adherent epithelial morphology. These cells are microsatellite stable (MSS) and harbor wild-type TP53, representing a common genotype in gastric cancer. AGS cells are widely employed as an in vitro model for gastric adenocarcinoma, facilitating investigation of gastric cancer cell biology, intracellular signaling, and pharmacological responses.
CCDC167 encodes a putative coiled-coil domain-containing protein, a structural motif recurring in proteins that mediate homo- and heterotypic interactions. Although its precise biological function and interaction partners remain uncharacterized, CCDC167 is hypothesized to participate in the assembly or regulation of macromolecular complexes that may influence gastric cancer cell phenotypes. Currently, no defined upstream regulators, downstream effectors, or interacting factors have been identified for CCDC167. The provided mechanistic summary indicates that knockout of CCDC167 in AGS polyclonal cells leads to ablation of CCDC167 protein function, with anticipated consequences on protein interaction networks that could alter gastric cancer cell behavior.
Given the uncharacterized nature of CCDC167, this polyclonal knockout model provides a valuable tool for deorphanizing the gene and dissecting its contribution to gastric adenocarcinoma biology. In the context of the AGS cell line??a widely used platform for gastric cancer signaling and drug response studies??loss of CCDC167 may reveal novel phenotypes related to proliferation, migration, or survival, thereby shedding light on its potential involvement in tumorigenic processes.
Key research applications include functional characterization via proliferation, migration, and colony formation assays; protein interaction screening using co-immunoprecipitation and mass spectrometry; transcriptomic profiling by RNA-seq to identify CCDC167-dependent gene expression changes; and cell cycle analysis by flow cytometry. Knockout validation can be performed by western blotting and, where antibodies are available, immunostaining. These cells are also suitable for biomarker discovery and pairwise comparison with parental AGS cells in drug sensitivity screens. For further technical details, please contact Ascent Research.
